Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Evaluation of Novel Endpoints As Treatment Outcome in Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of "Classical" and "Refined" Definition of Graft-Versus Host Disease Free and Relapse Free Survival for Registry-Based Studies

Simona Pagliuca, Antonio M Risitano, MD PhD, Flore Sicre De Fontbrune, MD, David Michonneau, MD PhD, Alban Villate, MD, Rudy Birsen, Camille Rouzaud, Aurelien Sutra del Galy, Nabergoj Mitja, MD, Regis Peffault De Latour, MD PhD, Marie Robin, MD PhD, Gérard Socié, MDPhD

Blood (2017) 130 (Supplement 1): 3311.

https://doi.org/10.1182/blood.V130.Suppl_1.3311.3311

Published: 2017

Journal Articles

Outcomes of Hematopoietic Stem Cell Transplantation after Chronic Graft Versus Host Disease and Evaluation of Revised Failure Free Survival in a Retrospective Analysis from Two Referral Centers.

Simona Pagliuca, Flore Sicre De Fontbrune, MD, Antonio M Risitano, MD PhD, David Michonneau, MD PhD, Alban Villate, MD, Rudy Birsen, Camille Rouzaud, Aurelien Sutra del Galy, Nabergoj Mitja, MD, Regis Peffault De Latour, MD PhD, Gérard Socié, MDPhD, Marie Robin, MD PhD

Blood (2017) 130 (Supplement 1): 4578.

https://doi.org/10.1182/blood.V130.Suppl_1.4578.4578

Published: 2017

Journal Articles

Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients

Marie Robin, MD PhD, Raphael Porcher, PhD, Laetitia Taurines, Bastien Oriano, Regis Peffault De Latour, MD PhD, Flore Sicre De Fontbrune, MD, David Michonneau, MD PhD, Nathalie Dhedin, MD, Christine Chomienne, MD PhD, Gérard Socié, MDPhD, Marie-Hélène Schlageter, PharmD

Blood (2017) 130 (Supplement 1): 4480.

https://doi.org/10.1182/blood.V130.Suppl_1.4480.4480

Published: 2017

Journal Articles

Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial

Régis Peffault de Latour, MD, Sylvie Chevret, MD PhD, Annalisa Ruggeri, MD, Felipe Suarez, MD PhD, Laetitia Souchet, MD, David Michonneau, MD PhD, Flore Sicre de Fontbrune, Tereza Coman, MD PhD, Marie t Rubio, MDPhD, Stéphanie Nguyen, MD PhD, Mohamad Mohty, MD PhD, Gerard Socie, MD PhD

Blood (2016) 128 (22): 65.

https://doi.org/10.1182/blood.V128.22.65.65

Published: 2016

Journal Articles

Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study

Simona Pagliuca, MD, Antonio M Risitano, MD PhD, Sylvie Chevret, Flore Sicre de Fontbrune, MD, Alienor Xhaard, MD, Tereza Coman, MD PhD, David Michonneau, MD PhD, Serena Marotta, MD, Mathilde Ruggiu, Swann Bredin, Regis Peffault de Latour, MD PhD, Gérard Socié, MD PhD, Marie Robin, MD PhD

Blood (2016) 128 (22): 2285.

https://doi.org/10.1182/blood.V128.22.2285.2285

Published: 2016

Journal Articles

Clinical Characteristics, Biological Markers and Comorbidity Indexes As Predictors of Transplant-Related Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: Which One Should We Choose?

Alienor Xhaard, MD, Renato Cunha, MD PhD, Marc Busson, Marie Robin, MD PhD, Nathalie Dhedin, MD, Tereza Coman, MD PhD, Aurelie Cabannes-Hamy, MD, Flore Sicre de Fontbrune, MD, David Michonneau, MD PhD, Gerard Socie, MD PhD, Rodrigo T. Calado, MD PhD, Regis Peffault De Latour, MD PhD

Blood (2016) 128 (22): 3478.

https://doi.org/10.1182/blood.V128.22.3478.3478

Published: 2016

NARROW

Evaluation of Novel Endpoints As Treatment Outcome in Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of "Classical" and "Refined" Definition of Graft-Versus Host Disease Free and Relapse Free Survival for Registry-Based Studies

Outcomes of Hematopoietic Stem Cell Transplantation after Chronic Graft Versus Host Disease and Evaluation of Revised Failure Free Survival in a Retrospective Analysis from Two Referral Centers.

Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients

Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial

Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study

Clinical Characteristics, Biological Markers and Comorbidity Indexes As Predictors of Transplant-Related Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: Which One Should We Choose?

Email alerts

ASH Publications

American Society of Hematology

Evaluation of Novel Endpoints As Treatment Outcome in Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of "Classical" and "Refined" Definition of Graft-Versus Host Disease Free and Relapse Free Survival for Registry-Based Studies

Outcomes of Hematopoietic Stem Cell Transplantation after Chronic Graft Versus Host Disease and Evaluation of Revised Failure Free Survival in a Retrospective Analysis from Two Referral Centers.

Potential of Plasmatic Biomarkers to Predict Acute Gvhd Severity: A Validation Study in a Prospective Cohort of 177 Patients

Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial

Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study

Clinical Characteristics, Biological Markers and Comorbidity Indexes As Predictors of Transplant-Related Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: Which One Should We Choose?

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only